Cardiovascular effects of anti-diabetes drugs

摘要: ABSTRACTIntroduction: Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From need reduce cardiovascular risk diabetes ensure that such is not exacerbated by drug treatments, governmental regulators manufacturers have focused on clinical trials evaluating outcomes.Areas covered: Findings from mechanistic of biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose co-transporter 2 (SGLT-2) inhibitors will be reviewed. These classes compared within context available outcomes data. Clinical implications new study regulations examined.Expert opinion: Recent studies provide a more comprehensive evaluation specific anti-diabetes therapy individuals with high risk. Long-term effects anti-hyperglycemic agents patients w...